MXCT vs BCYC vs BTBT vs PEPG vs CRSP

For growth investors, Bit Digital, Inc.

(BTBT) is the stronger pick with 264. 6% revenue growth year-over-year, versus -90. 0% for CRISPR Therapeutics AG (CRSP). Bit Digital, Inc. (BTBT) offers the better valuation at 9. 2x trailing P/E, making it the more compelling value choice. Analysts rate Bicycle Therapeutics plc (BCYC) a "Buy" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, CRISPR Therapeutics AG (CRSP) delivered a total return of -51.

3%, compared to -94. 9% for MaxCyte, Inc. (MXCT). Over 10 years, the gap is even starker: CRSP returned +289. 1% versus MXCT's -95. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), PepGen Inc.

(PEPG) is the lower-risk stock at -0. 10β versus Bit Digital, Inc. 's 3. 41β — meaning BTBT is approximately -3620% more volatile than PEPG relative to the S&P 500. On balance sheet safety, Bicycle Therapeutics plc (BCYC) carries a lower debt/equity ratio of 3% versus 21% for CRISPR Therapeutics AG — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Bit Digital, Inc.

(BTBT) is pulling ahead at 264. 6% versus -90. 0% for CRISPR Therapeutics AG (CRSP). On earnings-per-share growth, the picture is similar: Bit Digital, Inc. grew EPS 225. 0% year-over-year, compared to -49. 1% for CRISPR Therapeutics AG. Over a 3-year CAGR, CRSP leads at 100. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bit Digital, Inc.

(BTBT) is the more profitable company, earning 17. 3% net margin versus -165. 7% for CRISPR Therapeutics AG — meaning it keeps 17. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BTBT leads at 16. 8% versus -161. 9% for CRSP. At the gross margin level — before operating expenses — BCYC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, BTBT (0.

3% yield) pays a dividend. MXCT, BCYC, PEPG, CRSP do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, PepGen Inc.

(PEPG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 10)). Bit Digital, Inc. (BTBT) carries a higher beta of 3. 41 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PEPG: -86. 3%, BTBT: -61. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MXCT (Healthcare) and BCYC (Healthcare) and BTBT (Financial Services) and PEPG (Healthcare) and CRSP (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MXCT is a small-cap quality compounder stock; BCYC is a small-cap high-growth stock; BTBT is a small-cap high-growth stock; PEPG is a small-cap quality compounder stock; CRSP is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.